• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Neogen Announces the Appointment of New Board Member

    10/1/24 8:45:00 AM ET
    $NEOG
    $QGEN
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $NEOG alert in real time by email

    LANSING, Mich., Oct. 1, 2024 /PRNewswire/ -- Neogen® Corporation (NASDAQ:NEOG), an innovative leader in food safety solutions, announced today that it has appointed Thierry Bernard as a director to its Board, effective November 1, 2024.

    Neogen Corporation (PRNewsfoto/Neogen Corporation)

    "We are pleased to welcome Thierry Bernard to the Neogen Board of Directors and look forward to his guidance as the company continues in its commitment to fueling a brighter future for global food security," said Jim Borel, Neogen's Board Chair. "As a sitting CEO with a wealth of knowledge in science and technologies relevant to Neogen and its markets, we are confident that he will provide significant value to the Board during the company's continued growth." 

    Thierry Bernard is Chief Executive Officer of QIAGEN N.V. (NYSE:QGEN, Frankfurt Stock Exchange: QIA))), a leading global provider of sample-to-insight solutions that are used to transform biological materials into molecular insights. Mr. Bernard was named to the role in March 2020 after joining QIAGEN in 2015. Prior to his role at QIAGEN, Mr. Bernard spent 15 years with bioMérieux SA, where he held roles of increasing responsibility, most recently as Corporate Vice President, Global Commercial Operations, Investor Relations and the Greater China Region. He also held senior management roles in other leading international companies.

    About Neogen

    Neogen Corporation is committed to fueling a brighter future for global food security through the advancement of human and animal well-being. Harnessing the power of science and technology, Neogen has developed comprehensive solutions spanning the Food Safety, Livestock, and Pet Health & Wellness markets. A world leader in these fields, Neogen has a presence in over 140 countries with a dedicated network of scientists and technical experts focused on delivering optimized products and technology for its customers.

    Contact 

    [email protected]

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/neogen-announces-the-appointment-of-new-board-member-302263825.html

    SOURCE Neogen Corporation

    Get the next $NEOG alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NEOG
    $QGEN

    CompanyDatePrice TargetRatingAnalyst
    Neogen Corporation
    $NEOG
    7/29/2025Outperform → Mkt Perform
    William Blair
    Qiagen N.V.
    $QGEN
    6/24/2025$55.00Overweight
    Barclays
    Qiagen N.V.
    $QGEN
    4/4/2025Buy → Neutral
    Redburn Atlantic
    Qiagen N.V.
    $QGEN
    2/19/2025$52.00 → $42.00Outperform → Neutral
    Robert W. Baird
    Qiagen N.V.
    $QGEN
    1/6/2025$48.00Overweight → Equal-Weight
    Morgan Stanley
    Neogen Corporation
    $NEOG
    12/19/2024$15.00Buy
    Guggenheim
    Qiagen N.V.
    $QGEN
    12/10/2024$42.50 → $54.00Hold → Buy
    Jefferies
    Qiagen N.V.
    $QGEN
    10/17/2024$49.00Buy → Hold
    HSBC Securities
    More analyst ratings

    $NEOG
    $QGEN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    QIAGEN Exceeds Q3 2025 Outlook, Raises FY 2025 Adj. EPS Target, Announces Parse Acquisition and $500 Million Share Repurchase

    Q3 2025 results: Net sales of $533 million (+6% at actual rates); diluted EPS $0.60 Core sales +6% CER (constant exchange rates) driven by QIAstat-Dx (+11% CER), QuantiFERON (+11% CER) and Sample technologies (+3% CER) Solid adjusted operating income margin at 29.6% Adjusted diluted EPS $0.61 ($0.61 CER), above outlook for at least $0.58 CER Ongoing strong operating cash flow of $165 million Full-year 2025 outlook reaffirmed for net sales growth of about 4-5% CER (about 5-6% CER core sales) and raises adj. diluted EPS target to about $2.38 CER Acquisition of Parse Biosciences expands Sample technologies portfolio into the single-cell market, capturing AI-driven growth opportu

    11/4/25 1:04:00 PM ET
    $QGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    QIAGEN to acquire Parse Biosciences, expanding its Sample technologies portfolio into highly scalable single-cell solutions

    Parse Biosciences is a fast-growing innovator in single-cell sample preparation, with technologies used in more than 3,000 labs across over 40 countries Acquisition strengthens QIAGEN's presence in the rapidly growing single-cell market, accelerating growth across its industry-leading Sample technologies portfolio Parse provides Evercode, a highly differentiated instrument-free platform built for analyzing millions and billions of cells for large-scale AI-driven biology Single-cell market expected to nearly double by 2029, driven by AI-powered drug discovery and demand for high-scale, quantitative biological data Parse to be fully acquired for an upfront payment of approximatel

    11/4/25 1:03:00 PM ET
    $QGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    QIAGEN Launches New Automated Sexual Assault Sample Processing Kit at ISHI 2025

    New EZ2 DNA Investigator Sep&Prep Kit automates sexual assault sample processing, improving sperm DNA recovery and separation from victim DNA Workflow on EZ2 Connect Fx delivers high-quality DNA in under 2.5 hours, minimizing hands-on time and variability with current manual process QIAGEN to showcase new kit and forensics portfolio at upcoming ISHI 2025 meeting QIAGEN N.V. (NYSE:QGEN, Frankfurt Prime Standard: QIA)) today announced the launch of the EZ2 DNA Investigator Sep&Prep Kit, a fully automated solution for processing sexual assault samples, at the upcoming International Symposium on Human Identification 2025 (ISHI) from November 3-6 in Palm Beach, Florida. Developed spe

    10/30/25 5:05:00 PM ET
    $QGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $NEOG
    $QGEN
    SEC Filings

    View All

    SEC Form 6-K filed by Qiagen N.V.

    6-K - QIAGEN N.V. (0001015820) (Filer)

    11/5/25 8:59:24 PM ET
    $QGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 6-K filed by Qiagen N.V.

    6-K - QIAGEN N.V. (0001015820) (Filer)

    11/5/25 8:39:17 PM ET
    $QGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Neogen Corporation filed SEC Form 8-K: Leadership Update, Other Events, Financial Statements and Exhibits

    8-K - NEOGEN CORP (0000711377) (Filer)

    10/30/25 8:47:15 AM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $NEOG
    $QGEN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CEO Nassif Mikheal bought $1,106 worth of shares (177 units at $6.25) (SEC Form 4)

    4 - NEOGEN CORP (0000711377) (Issuer)

    11/7/25 12:20:20 PM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Amendment: New insider Nassif Mikheal claimed ownership of 620 shares (SEC Form 3)

    3/A - NEOGEN CORP (0000711377) (Issuer)

    11/7/25 12:12:52 PM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    CFO Riggsbee Richard Bryan was granted 178,855 shares (SEC Form 4)

    4 - NEOGEN CORP (0000711377) (Issuer)

    11/5/25 9:20:36 AM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $NEOG
    $QGEN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CEO Nassif Mikheal bought $1,106 worth of shares (177 units at $6.25) (SEC Form 4)

    4 - NEOGEN CORP (0000711377) (Issuer)

    11/7/25 12:20:20 PM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Director Gupta Aashima bought $99,987 worth of shares (16,000 units at $6.25), increasing direct ownership by 270% to 21,917 units (SEC Form 4)

    4 - NEOGEN CORP (0000711377) (Issuer)

    5/12/25 2:30:47 PM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Director Woteki Catherine E bought $29,831 worth of shares (5,770 units at $5.17), increasing direct ownership by 77% to 13,244 units (SEC Form 4)

    4 - NEOGEN CORP (0000711377) (Issuer)

    4/25/25 4:32:35 PM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $NEOG
    $QGEN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Neogen downgraded by William Blair

    William Blair downgraded Neogen from Outperform to Mkt Perform

    7/29/25 3:32:27 PM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Barclays initiated coverage on Qiagen with a new price target

    Barclays initiated coverage of Qiagen with a rating of Overweight and set a new price target of $55.00

    6/24/25 8:09:28 AM ET
    $QGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Qiagen downgraded by Redburn Atlantic

    Redburn Atlantic downgraded Qiagen from Buy to Neutral

    4/4/25 8:39:19 AM ET
    $QGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $NEOG
    $QGEN
    Leadership Updates

    Live Leadership Updates

    View All

    Neogen® Corporation Announces Appointment of Bryan Riggsbee as Chief Financial Officer

    Neogen® Corporation (NASDAQ:NEOG), a global leader of food safety solutions, is pleased to announce the appointment of Bryan Riggsbee as its new Chief Financial Officer effective November 3, 2025. Riggsbee will oversee Neogen's global finance organization and join the company's Executive Leadership Team, reporting directly to Chief Executive Officer Mike Nassif. To ensure a smooth transition, David Naemura is expected to remain with the Company until the end of the calendar year. Riggsbee brings over 25 years of financial leadership experience across the diagnostics and healthcare industries. He joins Neogen from bioMérieux where he served as Chief Financial Officer of its $2 billion Nort

    10/30/25 8:45:00 AM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Neogen Announces Board Transition with Appointment of Avi Pelossof and the Retirement of William Boehm

    Neogen® Corporation (NASDAQ:NEOG), an innovative leader in food safety solutions, announced today that William Boehm has chosen to retire from the Company's Board of Directors, effective October 23, 2025. Mr. Boehm has served on Neogen's Board since 2011 and currently serves on the Compensation & Talent Management Committee and chairs the Audit Committee. "On behalf of the entire Board and leadership team, I want to express our deep gratitude to Bill for his many years of dedicated service to Neogen," said James C. Borel, Chair of the Neogen Board of Directors. "Bill's insight, guidance, and commitment to our mission have been invaluable in shaping Neogen's path forward. His contributions

    8/14/25 4:15:00 PM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Neogen® Corporation Announces Appointment of Mike Nassif as CEO and President

    Neogen® Corporation (NASDAQ:NEOG), a global leader of food safety solutions, is pleased to announce the appointment of Mike Nassif as its new Chief Executive Officer and President, effective August 11, 2025. He also will join Neogen's Board of Directors at that time. Mr. Nassif succeeds John Adent who will, as previously announced, step down after an eight-year career at the company. Mr. Nassif brings a wealth of experience and a proven track record of success in the healthcare and diagnostics industry. Mr. Nassif joins Neogen from Siemens Healthineers, where he was Global President of the Point-of-Care Diagnostics business and instrumental in driving significant growth. "I am very exci

    7/24/25 9:00:00 AM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $NEOG
    $QGEN
    Financials

    Live finance-specific insights

    View All

    QIAGEN Exceeds Q3 2025 Outlook, Raises FY 2025 Adj. EPS Target, Announces Parse Acquisition and $500 Million Share Repurchase

    Q3 2025 results: Net sales of $533 million (+6% at actual rates); diluted EPS $0.60 Core sales +6% CER (constant exchange rates) driven by QIAstat-Dx (+11% CER), QuantiFERON (+11% CER) and Sample technologies (+3% CER) Solid adjusted operating income margin at 29.6% Adjusted diluted EPS $0.61 ($0.61 CER), above outlook for at least $0.58 CER Ongoing strong operating cash flow of $165 million Full-year 2025 outlook reaffirmed for net sales growth of about 4-5% CER (about 5-6% CER core sales) and raises adj. diluted EPS target to about $2.38 CER Acquisition of Parse Biosciences expands Sample technologies portfolio into the single-cell market, capturing AI-driven growth opportu

    11/4/25 1:04:00 PM ET
    $QGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    QIAGEN N.V. to Release Results for Q3 2025 and Hold Webcast

    QIAGEN N.V. (NYSE:QGEN) (Frankfurt Stock Exchange: QIA) today announced plans to release results for the third quarter of 2025. Press release date / time: Tuesday, November 4, shortly after 22:05 Frankfurt time / 21:05 London time / 16:05 New York time. Conference call date / time: Wednesday, November 5, at 15:30 Frankfurt time / 14:30 London time / 09:30 New York time. Three options for joining the conference call Register for call back connection - Click here: Connect me Service is available 15 minutes before the call starts Dial-in by phone U.S.: +1 929 477 0402 UK: +44 (0)330 165 3655 GER: +49 (0)69 6610 2480 Conference ID: 3763132 To avoid waiting time, please join the event

    10/13/25 8:24:00 AM ET
    $QGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Neogen Announces First-Quarter 2026 Results

    Revenue of $209.2 million Net Income of $36.3 million; Adjusted Net Income1 of $9.4 million Adjusted EBITDA1 of $35.5 million Completed divestiture of Cleaners & Disinfectants business, repaid $100.0 million of debt Welcomed Mike Nassif as Chief Executive Officer and President, effective August 11 Restructuring actions taken at the end of September to right-size the cost base Reaffirming full-year outlook 1 Non-GAAP financial measures; see explanations and reconciliations that follow Neogen Corporation (NASDAQ:NEOG) announced today the results of the first quarter ended August 31, 2025. "I see tremendous opportunity ahead to leverage Neogen's strong, longstanding l

    10/9/25 7:00:00 AM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $NEOG
    $QGEN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Neogen Corporation

    SC 13G - NEOGEN CORP (0000711377) (Subject)

    11/14/24 4:28:12 PM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form SC 13G filed by Neogen Corporation

    SC 13G - NEOGEN CORP (0000711377) (Subject)

    11/14/24 11:16:20 AM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form SC 13G filed by Qiagen N.V.

    SC 13G - QIAGEN N.V. (0001015820) (Subject)

    11/8/24 10:52:38 AM ET
    $QGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care